Chronic Schizophrenia
16
1
1
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.3%
1 terminated out of 16 trials
91.7%
+5.2% vs benchmark
25%
4 trials in Phase 3/4
18%
2 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (16)
Effect of tDCS on Inflammatory Biomarkers in Chronic Schizophrenia
Resourcefulness Group Intervention on Recovery and Quality of Life
Experience of Horticultural Group Therapy Among People With Chronic Schizophrenia
Study of Experience of High-frequency Repetitive Transcranial
An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms
Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia
Cognitive Remediation and Sheltered Employment in Schizophrenia
Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients
The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study
Integrated Psychological Therapy for Chronic Schizophrenia
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
Role of Nintendo Wii in Improving Negative Symptoms and Quality of Life in Chronic Schizophrenia
Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
Relation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation Schizophrenia
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
Oxygen Therapy in Schizophrenia